
Opinion|Videos|October 29, 2024
Utilization of 68Gallium PSMA-11 in Clinical Practice
Author(s)Oliver Sartor, MD
Key Takeaways
- 68gallium PSMA-11 gozetotide is essential for prostate cancer imaging but faces production and distribution challenges.
- Expanding production facilities and streamlining regulatory processes could enhance availability.
The panelist discusses how the limited availability of 68gallium PSMA-11 gozetotide in clinical practice poses challenges and suggests potential strategies to increase accessibility, such as expanding production facilities, improving distribution networks, and exploring alternative radiotracers with longer half-lives.
Advertisement
Discuss the availability of use 68gallium PSMA-11 gozetotide in clinical practice. What are potential strategies to increase availability?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Focal therapy for prostate cancer frequently used outside guideline-supported groups
2
Registry launches to assess real-world clinical utility of ArteraAI Prostate Test
3
Active surveillance use for low-risk prostate cancer reaches 93% in VA System
4
Ryan Flannigan, MD, highlights phase 2 data on ST-01 for chronic scrotal content pain
5










